CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Newsmakers
CytoDyn (OTC: CYDY) First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19
The Company’s Phase 2b/3 trial is for patients with severe and critically ill COVID-19 indications. Interim analysis will be conducted after results for first 50 patients are available. VANCOUVER, Washington, Apr 15, 2020 — CytoDyn […]
Healthcare
CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries
54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, Apr 30, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab […]
Healthcare
CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants
VANCOUVER, Washington, Mar 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]